HOME >> MEDICINE >> NEWS
UI-led study indicates surgery is the best treatment for severe Bell's palsy paralysis

IOWA CITY, Iowa -- How to best treat patients with Bell's palsy who are at high risk of permanent loss of facial muscle control has remained a controversial subject among physicians for decades. However, results of a 15-year study led by University of Iowa Health Care researchers may help to finally settle the debate.

"We hope these findings will help change the attitudes of a lot of different people," said Bruce Gantz, M.D., UI professor and head of otolaryngology.

Timing and strategy are critical when it comes to the subgroup of patients with Bell's palsy who are at the greatest risks for permanent damage. The study results indicate that identifying this patient population and their subsequent surgical treatment must occur within two weeks of the onset of paralysis.

"If we are going to have any impact, the surgery has to come within the first two weeks," Gantz stressed.

Bell's palsy is partial or complete facial muscle paralysis resulting from a certain dysfunctional cranial nerve that is believed to be damaged by the herpes simplex virus type I. The condition affects about 40,000 Americans per year. Although medication will help most individuals fully or almost fully recover from Bell's palsy paralysis, about 10 to 15 percent of patients will not recover unless additional measures are taken.

The study had three related goals, all attempting to answer the primary questions troubling many clinicians treating patients with Bell's palsy. The researchers wanted to determine how to best identify which patients will be left with poor outcomes, establish whether surgical decompression might improve these patients' chances of recovery, and finally, figure out what, if any, impact time had on treatment.

The study results were based on patient outcomes of individuals with Bell's palsy treated at the UI Hospitals and Clinics, the University of Michigan and the Baylor College of Medicine.

Through their investigation, the UI-led team determin
'"/>

Contact: Jennifer Cronin
jennifer-cronin@uiowa.edu
319-335-9917
University of Iowa
14-Oct-1999


Page: 1 2 3

Related medicine news :

1. UI-led study shows experimental anti-cancer drug also has anti-HIV properties
2. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
3. UMaine study looks at infants and chronic nighttime crying
4. Chronic pain treatments more effective when taken together, new study shows
5. UNC study: Most N.C. family practitioners engage in unrecognized community service
6. New study in Nature demonstrates protection against cell death during heart attack
7. UCSF study offers insight into human circadian rhythms
8. International breast cancer prevention study launches in the United States and Canada
9. UW study shows blacks and Latinos are more satisfied with physicians of the same race
10. Physicians may not be accurate in their confidence levels of their diagnoses, says Pitt study
11. Advertising by academic medical centers may risk eroding public trust, says study

Post Your Comments:
(Date:5/19/2013)... 2013 Healthcare leaders will gather at ... the Walt Disney World Swan and Dolphin in Orlando, ... innovation, care delivery and healthcare reform and implementation. , ... healthcare markets, with consolidation, efficiency and reduced ... Todd Ebert, Amerinet president and CEO. “There is a ...
(Date:5/19/2013)... The muscles in the human body are dependent ... the biggest and most significant nervous systems in the ... comprises of peripheral nerves that reside outside of the ... the limbs and hands, as well as other organs, ... due to trauma or physical injury, their functionality is ...
(Date:5/19/2013)... These molecular diagnostics market reports ... Japan, Italy, Germany and France:, ... practice, as well as key economic, regulatory, demographic, ... during the next five years. ,     An ... test formats, detection methodologies, trends in testing automation ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Farming methods ... seed in the ground 10,000 years ago. Most recently, ... farm productivity by using genetically engineered seeds and by ... seeing a backlash to these techniques due to the ... chemicals and a corresponding surge in interest in organic, ...
(Date:5/19/2013)... Agora Health Limited developed by Rachael Linkie is ... how to increase memory power naturally and effectively. The ... people re-new their entire health from the inside out. It ... a fatigued mind. In addition, the program helps people keep ... The author claimed that this program can help people overcome ...
Breaking Medicine News(10 mins):Health News:Healthcare Leaders Gather at 2013 Amerinet Member Conference to Share New Ways to Reduce Costs and Enhance Care Delivery 2Health News:Ultimate Neuropathy Support System Launched by Neuracel - Reaching New Heights in Herbal Medication for Peripheral Neuropathy 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 2Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 3Health News:How To Increase Memory Power | How “Agora Health Limited” Helps People Improve Their Memory Naturally And Effectively – Health Review 2
(Date:5/17/2013)... 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... JAKARTA , examining the selective JAK2 inhibitor ... both dose groups. The primary endpoint assessed the proportion ... with data reported in previous trials, the most common ... results will be presented at an upcoming medical congress. ...
(Date:5/17/2013)... -- Sinovac Biotech Ltd. (Nasdaq: SVA ), a ... today announced that it will release its unaudited financial results ... on Tuesday, May 28, 2013.  The Company will host a ... EDT (May 28, 2013 at 8:00 p.m. China Standard Time) ... on recent corporate developments. To access the conference ...
(Date:5/16/2013)... and ZURICH , May 17, 2013 /PRNewswire/ ... Science, Technology and Research (A*STAR) and Switzerland,s ... volunteer has been dosed in a Phase 1 clinical trial ... bacteriophage Qbeta virus-like particle (VLP) technology. In this first Phase ... vaccine candidate and its potential to protect against H1N1 influenza ...
Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6
Cached News: